secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001628280-25-034544
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option
--------------------------------------------------------------------------------

- Mary Szela appointed as Class III director; board expanded from six to seven members.
- Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.
- Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.
- Szela currently serves as CEO, President and Director of Trisalus Life Sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/0001628280-25-034544-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025034544/absc-20250707.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-034544

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer